A Phase I/IIa, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NI-0401 in Patients With Moderate to Severe Active Crohn's Disease

Trial Profile

A Phase I/IIa, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NI-0401 in Patients With Moderate to Severe Active Crohn's Disease

Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Foralumab (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions
  • Sponsors NovImmune SA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Mar 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top